CompletedPhase 2NCT00055302

Arimidex in McCune Albright Syndrome

Studying McCune-Albright syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Principal Investigator: AstraZeneca Arimidex Medical Science Director, MD
AstraZeneca
Intervention: Arimidex 1 mg(drug)
Enrollment: 40 enrolled
Eligibility: 10 years · FEMALE
Timeline: 2002 – 2015

Study locations (7)

Research Site, Montpellier, France
Research Site, Paris, France
Research Site, Berlin, Germany
Research Site, Erlangen, Germany
Research Site, Osnabrück, Germany
Research Site, Torino, Italy
Research Site, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00055302 on ClinicalTrials.gov

Other trials for McCune-Albright syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001727
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
National Institute of Dental and Craniofacial Research (NIDCR)

See all trials for McCune-Albright syndrome →

← Back to all trials